Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to Human CD51+CD61. Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, ovarian cancer and various other types of cancer.
The details of the immunogen for this antibody are not available.
Suitable for use in IP, IF, FuncS, FC, Neut, ELISA, ICC and most other immunological methods.
Tested positive against native human antigen
Predicted N terminal
H Chain: QVQLVESL Chain: EIVLTES
>95.0% as determined by analysis by SDS-PAGE.
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
The ITGAV protein undergoes post-translational cleavage to yield disulfide-linked heavy and light chains that combine with multiple integrin beta chains to form different integrins. This protein has been shown to heterodimerize with beta 1, beta 3, beta 5, beta 6, and beta 8; the heterodimer of alpha v and beta 3 is the Vitronectin receptor. This protein interacts with several extracellular matrix proteins to mediate cell adhesion and may play a role in cell migration. It is proposed that this protein may regulate angiogenesis and cancer progression. Alternative splicing results in multiple transcript variants that encode different protein isoforms. Note that the integrin alpha 5 and integrin alpha V chains are produced by distinct genes. The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling.
Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. They are known to participate in cell adhesion as well as cell-surface mediated signalling. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. CD51 encodes integrin alpha chain V. The I-domain containing integrin alpha V undergoes post-translational cleavage to yield disulfide-linked heavy and light chains, that combine with multiple integrin beta chains to form different integrins. Alpha-V integrins have been implicated in many developmental processes and are therapeutic targets for inhibition of angiogenesis and osteoporosis.